AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (T) - simulation-based training
Number of subjects: 17
Study 24149850 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - standard residency training
Number of subjects: 17
Study 24149850 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (T) - final total GOALS‐GH scores
Number of subjects: 17
Study 24149850 — intervention group
Group type: COMPARATOR
Intervention: Control group (C) - final total GOALS‐GH scores
Number of subjects: 17
Study 23273776 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week contingency management (CM) intervention for stimulant abuse
Number of subjects: 96
Study 21470279 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% lipid/heparin infusion (LHI)
Number of subjects: 13
Study 21470279 — intervention group
Group type: COMPARATOR
Intervention: saline/heparin infusion (SHI)
Number of subjects: 13
Study 18282679 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive Voice Response (IVR) support targeting physical activity and nutrition weight loss strategies
Number of subjects: 77
Study 18282679 — intervention group
Group type: COMPARATOR
Intervention: No-contact control
Number of subjects: 77
Study 16434754 — intervention group
Group type: COMPARATOR
Intervention: Saline before and after surgery (Group 1)
Number of subjects: 84
Study 16434754 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 300 microg x kg(‐1) iv before and saline after surgery (Group 2)
Number of subjects: 84
Study 16434754 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline before and ketamine 300 microg x kg(‐1) iv after surgery (Group 3)
Number of subjects: 84
Study 12844250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex) 8 mg administered on days 2-4 after chemotherapy
Number of subjects: 70
Study 12844250 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 12844250 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (Dex)
Number of subjects: 70
Study 11106119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 100 mg/m2 (arm A)
Number of subjects: 88
Study 11106119 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2 on days 1-8 plus cisplatin 70 mg/m2 (arm B)
Number of subjects: 88
Study 9574357 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthesia
Number of subjects: 90
Study 9574357 — intervention group
Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 90
Study 8225671 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase and adjunctive angioplasty
Number of subjects: 206
Study 6873872 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cimetidine (300 mg)
Number of subjects: 20
Study 6873872 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 20
Study 6873872 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cimetidine (300 mg every 8 hours for 8 days)
Number of subjects: 20
Study 30260748 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic sesame oil (DSO)
Number of subjects: 46
Study 30260748 — intervention group
Group type: COMPARATOR
Intervention: Diabetic control (DCON)
Number of subjects: 46
Study 29734881 — intervention group
Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg/day)
Number of subjects: 21
Study 29734881 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 27321122 — intervention group
Group type: EXPERIMENTAL
Intervention: ALA-DAG (2.5 g/d)
Number of subjects: 184
Study 27321122 — intervention group
Group type: COMPARATOR
Intervention: Control triacylglycerol (TAG) (2.5 g/d)
Number of subjects: 184
Study 23070695 — intervention group
Group type: EXPERIMENTAL
Intervention: Good Behavior Game (GBG) intervention
Number of subjects: 19
Study 23070695 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 19
Study 22206631 — intervention group
Group type: EXPERIMENTAL
Intervention: High attendance class
Number of subjects: 1825
Study 22206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Descending class
Number of subjects: 1825
Study 22206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Early-drop class
Number of subjects: 1825
Study 22206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising class
Number of subjects: 1825
Study 22206631 — intervention group
Group type: EXPERIMENTAL
Intervention: Low and no classes
Number of subjects: 1825
Study 18951439 — intervention group
Group type: EXPERIMENTAL
Intervention: Botox (BOT)
Number of subjects: 18
Study 18951439 — intervention group
Group type: EXPERIMENTAL
Intervention: Dysport (DYS)
Number of subjects: 18
Study 18951439 — intervention group
Group type: COMPARATOR
Intervention: Botox (BOT) and Dysport (DYS)
Number of subjects: 18
Study 17416761 — intervention group
Group type: COMPARATOR
Intervention: HPV-6
Number of subjects: 360
Study 17416761 — intervention group
Group type: COMPARATOR
Intervention: HPV-11
Number of subjects: 360
Study 17416761 — intervention group
Group type: COMPARATOR
Intervention: HPV-16
Number of subjects: 360
Study 17416761 — intervention group
Group type: COMPARATOR
Intervention: HPV-18
Number of subjects: 360
Study 16329657 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiviral therapy
Number of subjects: 0
Study 16329657 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15037535 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut diet
Number of subjects: 21
Study 15037535 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet
Number of subjects: 21
Study 10729719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS) during heelstick procedures
Number of subjects: 26
Study 10729719 — intervention group
Group type: COMPARATOR
Intervention: Heelstick procedures without NNS
Number of subjects: 26
Study 10729719 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonnutritive sucking (NNS)
Number of subjects: 26
Study 8871871 — intervention group
Group type: COMPARATOR
Intervention: IFN 5 MU, three times weekly by subcutaneous injection alone (n = 14)
Number of subjects: 27
Study 8871871 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN 5 MU in combination with cycles of deferoxamine at a dose of 80 mg kg‐1 per cycle (n = 13)
Number of subjects: 27
Study 1799151 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotiam (2 g intravenously with induction of anaesthesia)
Number of subjects: 711
Study 1799151 — intervention group
Group type: COMPARATOR
Intervention: Control (no cefotiam)
Number of subjects: 711
Study 6849542 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose corticosteroids (2 g methylprednisolone intravenously once a week plus 0.25 mg/kg prednisone orally daily)
Number of subjects: 13
Study 6849542 — intervention group
Group type: COMPARATOR
Intervention: Low dose corticosteroids (0.25 mg/kg prednisone orally daily)
Number of subjects: 13
Study 31124400 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized response technique
Number of subjects: 0
Study 31034349 — intervention group
Group type: EXPERIMENTAL
Intervention: In-office bleaching with high hydrogen peroxide concentration (Opalescence Boost PF 40%, Ultradent) for 40 minutes in three sessions (first, eighth, and 15th days of treatment)
Number of subjects: 135
Study 31034349 — intervention group
Group type: EXPERIMENTAL
Intervention: At-home bleaching with low carbamide peroxide concentration (Opalescence PF 10%, Ultradent) for 60 minutes daily for 15 days
Number of subjects: 135
Study 31034349 — intervention group
Group type: COMPARATOR
Intervention: Control group (no bleaching agent applied)
Number of subjects: 135
Study 27631892 — intervention group
Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention (three session nurse-led program)
Number of subjects: 155
Study 27631892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 155
Study 27631892 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 155
Study 26480904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibrotactile stimulus from Vertiguard™ for ten days
Number of subjects: 13
Study 26480904 — intervention group
Group type: COMPARATOR
Intervention: Equipment without the stimulus (Control Group)
Number of subjects: 13
Study 23635680 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate scan after urination (within 5 minutes)
Number of subjects: 221
Study 23635680 — intervention group
Group type: COMPARATOR
Intervention: Deferred scan (at least 15 minutes after urination)
Number of subjects: 221
Study 23635680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 221
Study 21670177 — intervention group
Group type: EXPERIMENTAL
Intervention: Dispersible tablet
Number of subjects: 184
Study 21670177 — intervention group
Group type: COMPARATOR
Intervention: Crushed tablet
Number of subjects: 184
Study 21670177 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 184
Study 18811878 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP), 500 microg twice daily
Number of subjects: 36
Study 18811878 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 16611285 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. for 7 days
Number of subjects: 402
Study 16611285 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin 200 mg b.d. for 7 days followed by the same schedule of group A
Number of subjects: 402
Study 16611285 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg b.d., clarithromycin 500 mg b.d. and tinidazole 500 mg b.d. plus lactoferrin 200 mg b.d. for 7 days
Number of subjects: 402
Study 14557443 — intervention group
Group type: EXPERIMENTAL
Intervention: iv OXM (3.0 pmol/kg.min)
Number of subjects: 13
Study 11326143 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant supplementation (n = 30)
Number of subjects: 60
Study 11326143 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study 8855804 — intervention group
Group type: EXPERIMENTAL
Intervention: T enanthate 200 mg im every 20 days
Number of subjects: 51
Study 8855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual T cyclodextrin (SLT) 2.5 mg three times daily
Number of subjects: 51
Study 8855804 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual T cyclodextrin (SLT) 5.0 mg three times daily
Number of subjects: 51
Study 1535876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐osmolality contrast medium (LOM)
Number of subjects: 929
Study 1535876 — intervention group
Group type: COMPARATOR
Intervention: High‐osmolality contrast medium (HOM)
Number of subjects: 929
Study 1535876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐osmolality contrast medium (LOM) in angiocardiography
Number of subjects: 929
Study 1535876 — intervention group
Group type: COMPARATOR
Intervention: High‐osmolality contrast medium (HOM) in angiocardiography
Number of subjects: 929
Study 1535876 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐osmolality contrast medium (LOM) in body CT
Number of subjects: 929
Study 1535876 — intervention group
Group type: COMPARATOR
Intervention: High‐osmolality contrast medium (HOM) in body CT
Number of subjects: 929
Study 6441778 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 types of hypocaloric parenteral nutrition (75 g/day amino acids with different carbohydrates: 120 g dextrose, 120 g or 200 g dextrose/fructose/xylitol)
Number of subjects: 40
Study 6441778 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 75 g/day of dextrose
Number of subjects: 40
Study 31919514 — intervention group
Group type: EXPERIMENTAL
Intervention: HE‐HFD (hyperenergetic, high‐fat diet; +50% energy, 65% total energy as fat)
Number of subjects: 12
Study 31919514 — intervention group
Group type: EXPERIMENTAL
Intervention: HE‐HFD (hyperenergetic, high‐fat diet)
Number of subjects: 12
Study 31919514 — intervention group
Group type: COMPARATOR
Intervention: Control diet (36% total energy as fat)
Number of subjects: 12
Study 31006805 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole pinto beans (wPB) supplemented into HSF diet (5% wt:wt)
Number of subjects: 44
Study 31006805 — intervention group
Group type: EXPERIMENTAL
Intervention: Hulls of pinto beans (hPB) supplemented into HSF diet (0.5% wt:wt)
Number of subjects: 44
Study 31006805 — intervention group
Group type: COMPARATOR
Intervention: High saturated fat diet (HSF)
Number of subjects: 44
Study 31006805 — intervention group
Group type: COMPARATOR
Intervention: Normal-fat diet (NF)
Number of subjects: 44
Study 28538321 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial back squat
Number of subjects: 15
Study 28538321 — intervention group
Group type: COMPARATOR
Intervention: Full back squat
Number of subjects: 15
Study 27265097 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute therapist-delivered brief intervention (Project Sync)
Number of subjects: 409
Study 27265097 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care (EUC) condition (resource brochure)
Number of subjects: 409
Study 25135191 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care intervention
Number of subjects: 626
Study 25135191 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 626
Study 22712624 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group (graft positioned 1 mm apical to CEJ, flap 1 mm coronal to CEJ)
Number of subjects: 15
Study 22712624 — intervention group
Group type: COMPARATOR
Intervention: Control group (graft and flap positioned at the level of CEJ)
Number of subjects: 15
Study 19295270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cavity care patient guidance including teaching good brushing methods, O'Leary's Plaque Control Record (PCR) as a cleanliness index, and Eilers' Oral Assessment Guide (OAG) as an overall index after April 2006
Number of subjects: 20
Study 19295270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cavity care patient guidance
Number of subjects: 20
Study 18021525 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS) for 20 min per session, 5 days weekly for 6 weeks.
Number of subjects: 78
Study 18021525 — intervention group
Group type: COMPARATOR
Intervention: Standardized functional exercise program (Control group).
Number of subjects: 78
Study 15667867 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 35
Study 15667867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 11139532 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 microgram misoprostol
Number of subjects: 2058
Study 11139532 — intervention group
Group type: COMPARATOR
Intervention: 1 ml syntometrine
Number of subjects: 2058
Study 9617377 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of higher dose metoclopramide (3 mg/kg x2) plus dexamethasone and diphenhydramine
Number of subjects: 70
Study 9617377 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-HT3 receptor antagonist plus dexamethasone
Number of subjects: 70
Study 9617377 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal antiemetic prophylaxis for delayed emesis induced by moderately emetogenic chemotherapy
Number of subjects: 70
Study 7875420 — intervention group
Group type: EXPERIMENTAL
Intervention: Enprostil
Number of subjects: 165
Study 7875420 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 165
Study 2453704 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol 250-500 mg/m2 body surface
Number of subjects: 0
Study 31738463 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO intervention (robotic seal), 30 minutes, 5 days a week for 6 weeks
Number of subjects: 11
Study 31738463 — intervention group
Group type: EXPERIMENTAL
Intervention: PARO intervention (robotic seal)
Number of subjects: 11
Study 29653629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline (100 mg once a day for 28 days)
Number of subjects: 1000
Study 29653629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1000
Study 29653629 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Number of subjects: 1000
Study 28159821 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 minutes hemostatic compression time
Number of subjects: 568
Study 28159821 — intervention group
Group type: COMPARATOR
Intervention: 60 minutes hemostatic compression time
Number of subjects: 568
Study 26216371 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvenous leads implantation and right ventricular (RV) pacing
Number of subjects: 206
Study 26216371 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency of RV pacing (>40%)
Number of subjects: 206
Study 23937708 — intervention group
Group type: EXPERIMENTAL
Intervention: Nightly sildenafil (50 mg)
Number of subjects: 100
Study 23937708 — intervention group
Group type: COMPARATOR
Intervention: On-demand sildenafil (50 mg)
Number of subjects: 100
Study 20086023 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18234466 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin (0.5 mg/kg)
Number of subjects: 160
Study 18234466 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (5000 IU)
Number of subjects: 160
Study 16490582 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release hydromorphone hydrochloride (ER hydromorphone HCl) administered every 24 hours
Number of subjects: 343
Study 16490582 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release hydromorphone hydrochloride (IR hydromorphone HCl) tablets as rescue medication
Number of subjects: 343
Study 12746764 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous diphenhydramine administration
Number of subjects: 64
Study 12746764 — intervention group
Group type: COMPARATOR
Intervention: Liposomal amphotericin B (L-AMB) infusion
Number of subjects: 64
Study 10952475 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg alone
Number of subjects: 12
Study 10952475 — intervention group
Group type: COMPARATOR
Intervention: Thioridazine 50 mg alone
Number of subjects: 12
Study 10952475 — intervention group
Group type: EXPERIMENTAL
Intervention: Zaleplon 20 mg and Thioridazine 50 mg coadministration
Number of subjects: 12
Study 9282974 — intervention group
Group type: EXPERIMENTAL
Intervention: Crohn's disease patients
Number of subjects: 36
Study 9282974 — intervention group
Group type: COMPARATOR
Intervention: Control patients
Number of subjects: 36
Study 8337731 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular QN alone (quinine dihydrochloride 20 mg salt/kg as a loading dose, followed by 10 mg salt/kg 12 hourly for a total of 6 doses)
Number of subjects: 80
Study 8337731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular QN plus one intramuscular injection of SD/PM (sulfadoxine 25 mg/kg, pyrimethamine 1.25 mg/kg)
Number of subjects: 80
Study 8337731 — intervention group
Group type: EXPERIMENTAL
Intervention: SD/PM
Number of subjects: 80
Study 3806204 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy (1-(2-chloroethyl)-1-nitrosourea, vincristine, and prednisone)
Number of subjects: 74
Study 3806204 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (Control)
Number of subjects: 74
Study 3806204 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 74
Study 31476757 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin infiltration application + fluoridated toothpaste and flossing use
Number of subjects: 41
Study 31476757 — intervention group
Group type: COMPARATOR
Intervention: Fluoridated toothpaste and flossing use
Number of subjects: 41
Study 31197822 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy) with an OTT of 7 days (group A)
Number of subjects: 810
Study 31197822 — intervention group
Group type: COMPARATOR
Intervention: Short-course radiotherapy (5 × 5 Gy) with an OTT of 8-13 days (group B)
Number of subjects: 810
Study 31197822 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy) with an OTT of 5-7 weeks (group C)
Number of subjects: 810
Study 31197822 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course radiotherapy (5 × 5 Gy) with an OTT of 8-13 weeks (group D)
Number of subjects: 810
Study 31197822 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course radiotherapy (25 × 2 Gy) with an OTT of 9-11 weeks (group E)
Number of subjects: 810
Study 31197822 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-course radiotherapy (25 × 2 Gy) with an OTT of 12-14 weeks (group F)
Number of subjects: 810
Study 28741871 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (0.03 to 5 mg)
Number of subjects: 51
Study 28741871 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697 (≥1.8 mg)
Number of subjects: 51
Study 28741871 — intervention group
Group type: EXPERIMENTAL
Intervention: RG7697
Number of subjects: 51
Study 26383102 — intervention group
Group type: EXPERIMENTAL
Intervention: Xpert MTB/RIF
Number of subjects: 3604
Study 26383102 — intervention group
Group type: COMPARATOR
Intervention: Microscopy
Number of subjects: 3604
Study 24225972 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based self-help intervention
Number of subjects: 58
Study 24225972 — intervention group
Group type: COMPARATOR
Intervention: Internet-based intervention with 3 supplemental counseling sessions
Number of subjects: 58
Study 22360134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) continuous regimen: 1,000 AU/week for the entire study period (Group 1)
Number of subjects: 32
Study 22360134 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) pre-seasonal regimen: 5,000 AU/week for 10 weeks/year for 2 years (Group 2)
Number of subjects: 32
Study 22360134 — intervention group
Group type: COMPARATOR
Intervention: On demand drug therapy alone (Group 3)
Number of subjects: 32
Study 19666432 — intervention group
Group type: EXPERIMENTAL
Intervention: Propylthiouracil (PTU)
Number of subjects: 50
Study 19666432 — intervention group
Group type: EXPERIMENTAL
Intervention: Methimazole (MMZ)
Number of subjects: 50
Study 19666432 — intervention group
Group type: COMPARATOR
Intervention: Both PTU and MMZ
Number of subjects: 50
Study 17940869 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of HBV risk among Chinese Americans
Number of subjects: 442
Study 17940869 — intervention group
Group type: EXPERIMENTAL
Intervention: Doctor recommendation for HBV testing
Number of subjects: 442